Usa hospital covid-19 patient Usa

Remdesivir combo reduces COVID-19 recovery time

Reading now: 648
www.cidrap.umn.edu

A combination of the antiviral drug remdesivir and the anti-inflammatory drug baricitinib reduced recovery time and accelerated improvement, especially among patients receiving supplemental oxygen without invasive ventilation, according to a large, international study of hospitalized COVID-19 patients published in the New England Journal of Medicine today.Severe COVID-19 appears to be associated with an exaggerated inflammatory response in some patients, leading researchers to consider anti-inflammatory medications like baricitinib as potential therapies.

Remdesivir, approved by the US Food and Drug Administration on Oct 22 to treat hospitalized COVID patients, has thus far met with mixed results when used alone.Researchers at 67 trial

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA